Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Alveltamig

Bispecific antibody · Immune activation, directed at delta-like protein 3 (DLL3) and T-cell surface glycoprotein CD3 · developed by AbbVie

Phase 2 Most advanced trial
ABBV Developer

What is Alveltamig?

Alveltamig is a trispecific T-cell engaging antibody that binds two different epitopes of DLL3, a Notch pathway protein overexpressed on various cancer cells, and CD3 on cytotoxic T-lymphocytes. It redirects these T-cells to kill DLL3-expressing tumor cells. It is being studied in extensive-stage small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
delta-like protein 3 (DLL3), T-cell surface glycoprotein CD3
Mechanism
Immune activation, directed at delta-like protein 3 (DLL3) and T-cell surface glycoprotein CD3
Pathways
Notch signaling
Therapy area
Oncology
Developer
AbbVie (ABBV)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
JS9TS9U9N4

Conditions studied

Extensive Stage-Small Cell Lung Cancer (ES-SCLC)

Other drugs acting on DLL3

More from AbbVie

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind Alveltamig

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.